Imipenem/cilastatin reduces cyclosporin-induced tubular damage in kidney transplant recipients.
Carmellini
M
M
Department of Oncology, University of Pisa, Italy.
Matteucci
E
E
Boggi
U
U
Cecconi
S
S
Giampietro
O
O
Mosca
F
F
D000118:Acetylglucosaminidase / Q000652:urine; D000419:Albuminuria; D019072:Antibiotic Prophylaxis; D002442:Ceftazidime / Q000627:therapeutic use*; D015377:Cilastatin / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D004231:Diuresis / Q000187:drug effects; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D007684:Kidney Tubules / Q000473:pathology; D008074:Lipoproteins / Q000097:blood; D011480:Protease Inhibitors / Q000627:therapeutic use; D013845:Thienamycins / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D008074:Lipoproteins; D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D016572:Cyclosporine; D002442:Ceftazidime; D003404:Creatinine; D000118:Acetylglucosaminidase